Author Archives: admin


Stem Cell Clinic > Articles by: admin

LIDDS Announces Data on Liproca Depot from Open Label Extension Study

By Global News Feed

UPPSALA, SWEDEN – LIDDS AB (publ) announced today results from the voluntary open-label extension (OLE) of LPC-004 in prostate cancer following the Liproca® Depot Phase IIb. Results showed that 50 % of the patients remained at low PSA levels for at least 10 months from their first Liproca® Depot injection and were therefore not treated with a second injection. PSA levels in the remaining six patients were in average reduced by 28 % at 2 months post treatment and reduced PSA levels remained in 2 patients at the end of the study with PSA reductions of 43 % and 73 %.

Read the original post:
LIDDS Announces Data on Liproca Depot from Open Label Extension Study

Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs

By Global News Feed

Amsterdam, The Netherlands, September 30, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company focused on the development of innovative natural killer (NK) cell-based medicines for the treatment of life-threatening diseases, today announces its unaudited interim results for the six months ended June 30, 2020, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

Go here to read the rest:
Kiadis announces results for the six months ended June 30, 2020 and significant progress made to date in 2020 in all development programs

Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with…

By Global News Feed

-ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for adrenocortical insufficiency specifically designed for children

See the article here:
Eton Pharmaceuticals Announces FDA Approval of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) as Replacement Therapy in Pediatric Patients with...

ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1

By Global News Feed

-- Phase 2b study in healthy volunteers met primary endpoints of overall safety and induction of mucosal immunity ---- BPZE1 prevented colonization from re-vaccination/challenge in 90% of subjects with no vaccine related serious adverse events --WESTON, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD) today presented positive topline Phase 2b trial results of its lead pertussis vaccine candidate BPZE1 at the virtual World Vaccine Congress. BPZE1, a live attenuated pertussis vaccine, met both primary endpoints of overall safety and induction of mucosal immunity.“With limited duration of immunity and the inability to significantly stop transmission, acellular vaccines have been associated with the resurgence of whooping cough,” said Cheryl Keech, M.D., Ph.D., chief medical officer and executive vice president of clinical research at ILiAD. “We need a vaccine that can effectively stop the spread of pertussis. In this study, BPZE1 demonstrated reduced nasal colonization and induction of durable mucosal immunity — two key factors necessary for the prevention of transmission and reduction of epidemic pertussis cycles.”

See original here:
ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1

Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

By Global News Feed

WESTLAKE VILLAGE, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced the commencement of an underwritten public offering of 4,000,000 shares of its common stock. In addition, the Company intends to grant the underwriters a 30-day option to purchase up to 600,000 additional shares of its common stock.

Read more:
Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal

By Global News Feed

CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus, and dismissed Catalyst's case. Catalyst is currently reviewing the District Judge's decision, which it believes to be erroneous, and intends to appeal the result to the Eleventh Circuit Court of Appeals.

Visit link:
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal

Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

By Global News Feed

WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,248,750 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to Prelude Therapeutics from the offering were approximately $181.9 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Prelude Therapeutics.

See the rest here:
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

→←